CVRx announced the immediate termination of Robert John as Chief Revenue Officer on August 10, 2026, citing a revised commercial outlook and the need to improve execution. Paul Verrastro has been appointed Interim Head of Sales while the company searches for a permanent successor. Mr. Verrastro brings over 30 years of medical device experience and recently served as Chief Marketing and Strategy Officer. CVRx operates in the medical device industry, developing and commercializing neuromodulation solutions for cardiovascular diseases.

CVRx reported second quarter 2026 total revenue of $15.7 million, a 16% increase year-over-year, driven by U.S. sales growth to $14.8 million and an expansion in active implanting centers to 258. The company announced updated full-year 2026 guidance, projecting total revenue between $58.0 million and $60.0 million and operating expenses between $99.0 million and $101.0 million, citing headwinds from fewer sales territories and lower productivity. Additionally, Humana issued a Medicare Advantage coverage policy for Barostim therapy effective May 1, 2026. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases.

Chief Financial Officer Jared Oasheim has announced his intention to resign from CVRx, Inc. to pursue other professional opportunities. He will remain in his role until a successor is appointed, with a full-time employment through at least August 31, 2026, or 30 days post-transition, followed by a consulting arrangement through February 2027 at $245 per hour. The company entered into an Employment Transition Agreement on June 8, 2026, which includes a $262,000 cash payment for transition assistance, eligibility for his 2026 cash incentive, and an extension of the post-termination exercise period for certain stock options. CVRx, Inc. is a medical device company focused on cardiovascular health technology.